ClinicalTrials.gg
CompletedNCT00337935Updated May 13, 2013Results posted

A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

A Phase 2 interventional study of Epoetin Alfa and Standard of care in Renal Failure , Chronic and Anemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-13.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.

Enrollment
13th of 25
157 · median 157
Started
2006
with 2 others
Phase 2
5 of 25
none open now
Registered
5th of 25
by date
Lead sponsor
7 of 25
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 13th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 5th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to show that giving PROCRIT (Epoetin alfa) every 2 weeks to increase the hemoglobin (Hb) level and then to adjust the PROCRIT (Epoetin alfa) dose every 4 weeks (Q4W) to maintain Hb levels, is safe and effective in patients with anemia from Chronic Kidney Disease (CKD), not on dialysis, who reside in long-term care facilities. In this study the frequency of PROCRIT (Epoetin alfa) dosing is under investigation.

Read the detailed description

PROCRIT (Epoetin alfa) is a brand of recombinant human erythropoietin (rHuEPO). Erythropoietin is a hormone produced in the kidney. Its function is to stimulate the production of red blood cells in the bone marrow. Many patients with Chronic Kidney Disease (CKD) do not produce enough erythropoietin and thus develop anemia (a reduction in red blood cell levels). This can cause them to feel tired.

PROCRIT (Epoetin alfa) is approved by the United States Food and Drug Administration (FDA) for the treatment of anemia (low red blood cell count) in patients with CKD (not on dialysis). The approved dosing frequency for PROCRIT (Epoetin alfa) in patients with CKD is one injection three times per week. Although PROCRIT (Epoetin alfa) is approved by the FDA for the treatment of certain types of anemia at different dosing schedules, the dosing schedules that will be used in this study are investigational in CKD. An investigational use is one that is currently not approved by the FDA.

This is an open-label, randomized (patients are assigned different treatments based on chance), multi-center, controlled study of patients with anemia of Chronic Kidney Disease (CKD), not on dialysis, who reside in long-term care facilities. Approximately 156 patients with CKD, not on dialysis, who have not received an erythropoietin receptor agonist (a drug that stimulates red blood cell production) for eight weeks immediately prior to screening (Week -1) and who have a hemoglobin (Hb, a measure of the number of red blood cells), less than 11 g/dL at screening will be eligible to participate. Patients will be evaluated for eligibility during a one-week screening phase. Eligible patients will be randomized in a 3:1 ratio to a PROCRIT (Epoetin alfa) group or to the control group for a period of 26 weeks. Randomization is done through a computer that randomly assigns the subject by chance (like rolling dice) to one of two groups (No one can choose the group to which they will be assigned.). They will have a 3 to 1 chance of being assigned to Group 1 versus Group 2, which means that out of every 4 patients entering the study 3 will receive PROCRIT (Epoetin alfa) and 1 will not.

Group 1 -will receive PROCRIT (Epoetin alfa) 20,000 Units (U) every 2 weeks until the hemoglobin reaches 11.0 g/dL or higher and remains at this level for two measurements in a row. At Week 6 or thereafter, the 20,000 Unit dose may be adjusted upward or downward as required to obtain the two consecutive hemoglobin measurements. Once the two consecutive measurements have been achieved, PROCRIT (Epoetin alfa) will be given every 4 weeks (Q4W) at double the previous dose to obtain a target hemoglobin of up to 12.0 g/dL. There will be no conversion to Q4W before Week 6 or after Week 18. If the hemoglobin drops, patients may go back to receiving PROCRIT (Epoetin alfa) every 2-weeks. If the hemoglobin rises above 12.0 g/dL, patients will not receive another dose of PROCRIT (Epoetin alfa) until the Hg level is below 12.0 g/dL. If the hemoglobin rises rapidly, patients will not receive another dose of PROCRIT (Epoetin alfa) until the rise is 1 g/dL or less in a 2-week period. The maximum amount of PROCRIT (Epoetin alfa) that this group can receive is 60,000 Units over a 4-week period. All doses of PROCRIT (Epoetin alfa) are injected under the skin (subcutaneous).

Group 2 - will not receive any PROCRIT (Epoetin alfa). This group will continue to receive the care that they are now receiving from their physician and the physician will review all lab results.

Since a lack of iron could interfere with the ability of patients to make red blood cells, patients in both groups will have iron levels checked at the screening visit and during the study. Based on the results of iron tests, the study doctor may prescribe an oral (by mouth) or intravenous (injection) iron supplement during the study. If the need for iron supplementation is determined, patients will receive iron supplementation no matter which group they are in.

Every two weeks a study visit will be performed. At each visit, blood pressure and heart rate will be checked, and blood will be drawn for all patients and sent to the central laboratory for complete blood count (CBC). The Hb by CBC will be used for efficacy analysis ( to measure the effectiveness of the study drug in increasing the hemoglobin level). Hb testing by HemoCue will be performed every two weeks on-site for PROCRIT (Epoetin alfa) group patients, for the purpose of real-time dosing decisions. (HemoCue is the brand name of a portable hemoglobin test that uses a drop of blood to obtain immediate hemoglobin measurements). PROCRIT (Epoetin alfa) will be administered at a dose based on the HemoCue Hb measurement. Full hematology panel, serum chemistry, and iron status will be assessed at intervals throughout the study by a central laboratory. The number of units of packed red blood cells (PRBC) transfused, pre-transfusion Hb level, and the reasons for transfusion will be collected. Hemoglobin response will also be measured. A patient exhibiting a hemoglobin response will have two consecutive Hb measurements at least 1 g/dL greater than baseline any time during the study or have two consecutive Hb measurements >= 11.0 g/dL at any time during the study. Falls, activities of daily living (ADLs), and mobility will be assessed during the study. Clinical laboratory results, blood pressure and heart rate, and the incidence and severity of adverse events will be monitored during the study.

The study hypothesis is that the mean Hb change from baseline to the end of study will be significantly higher in the PROCRIT (Epoetin alfa) group over the control group. Group 1 patients will receive a maximum of 13 doses of PROCRIT (Epoetin alfa) by subcutaneous injection (under the skin) for up to 26 weeks. Dosage is based on the hemoglobin measurement done at each visit. Doses will be started at an every 2-week interval and may be increased to every four weeks. The maximum dose that can be given is 60,000 Units of PROCRIT (Epoetin alfa) over a 4-week period. Any PROCRIT (Epoetin alfa) dose over 40,000 Units will be administered in two separate injections.

03

Conditions studied

  • Renal Failure , Chronic
  • Anemia

Keywords

  • Long Term Care Facilities
  • subcutaneous injections
  • PROCRIT
  • Epoetin alfa
  • Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic Kidney Disease (CKD) Stage 3, 4, or 5 (not on dialysis), (GFR) [\<60 mL/min/1.73 m2], or CKD Stage 2 (GFR 61-90 mL/min/1.73 mm2) with evidence of kidney damage (defined as structural or functional abnormalities of the kidneys) for greater than 3 months
  • \<11 g/dL measured at screening and a stable creatinine over the last 3 months
  • expected to stay in a Long Term Care (LTC) facility for at least six months
  • not receiving erythropoietic agents within eight weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • No significant hematological disease (including, but not limited to, myelodysplastic syndrome, hematological , hemolytic syndromes, hemoglobinopathy), or with a current diagnosis of anemia due to blood loss (e.g., hemolysis or gastrointestinal bleeding) or any cause of anemia other than CKD (e.g., hypothyroidism, )
  • No history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months prior to screening (prior superficial thrombophlebitis is not an exclusion criterion), or a history of cerebrovascular accident (CVA), (TIA), Acute Coronary Syndrome (ACS), or other arterial thrombosis within 6 months before study entry. [ACS includes Unstable Angina, Q wave Myocardial Infarction and non-Q wave Myocardial Infarction]
  • No uncontrolled or severe cardiovascular disease including uncontrolled hypertension (systolic BP > 170 mm/Hg, or diastolic BP > 100 mm/Hg), or congestive heart failure ( (NYHA) Class IV)
  • No known solid tumor malignancy, receiving chemotherapy for cancer or having major surgery within one month prior to screening or expected during study participation
  • No history of receiving a transplanted organ, or scheduled to receive an organ transplant during the course of the study, with the exception of a corneal transplant.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Epoetin Alfa

    Drug: Epoetin Alfa

  • Other
    Group 2

    Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).

    Other: Standard of care

Interventions

  • Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks

  • OtherStandard of care

    Also known as: Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).

06

What researchers measure

Primary outcomes

  1. Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks)

    Time frame: Week 0 to Week 26

Secondary outcomes

  1. The Number of Patients Achieved a Hemoglobin Response.

    Hemoglobin reponse was defined as 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL

    Time frame: Week 0 to Week 26

  2. Time to Hemoglobin Response

    Time to hemoglobin reponse was defined as the time between individual treatment start date and the first of 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL. Note: Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment.

    Time frame: Week 0 to Week 26

07

Results

Posted May 13, 2013
Limitations and caveats
Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment.

Participant flow

Participant flow — Overall Study
MilestoneStandard of CarePROCRIT (Epoetin Alfa)
Started39118
Completed2991
Not completed1027
Withdrew: Adverse event25
Withdrew: Death28
Withdrew: Physician decision11
Withdrew: Lost to follow-up01
Withdrew: Protocol violation43
Withdrew: Withdrawal by subject17
Withdrew: Other01
Withdrew: Lack of efficacy01

Outcome measures

PrimaryMean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks)
Time frame:
Week 0 to Week 26
Reported as:
Mean · g/dL
Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks)
g/dLStandard of CarePROCRIT (Epoetin Alfa)
Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks)0.3 ± 1.30.9 ± 1.0
Statistical analysis
  • Standard of Care vs PROCRIT (Epoetin Alfa) · ANCOVA · p = .0062 (a priori theshold for statistical significance was p=0.05) · Mean difference (net): 0.6 · 95% CI 0.2 to 0.9Baseline Hemoglobin was used as a covariate.
SecondaryThe Number of Patients Achieved a Hemoglobin Response.

Hemoglobin reponse was defined as 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL

Time frame:
Week 0 to Week 26
Reported as:
Number · participants
The Number of Patients Achieved a Hemoglobin Response.
participantsStandard of CarePROCRIT (Epoetin Alfa)
The Number of Patients Achieved a Hemoglobin Response.2197
Statistical analysis
  • Standard of Care vs PROCRIT (Epoetin Alfa) · Chi-squared · p = <0.001 (A priori threshold for statistical significance p=0.05)
SecondaryTime to Hemoglobin Response

Time to hemoglobin reponse was defined as the time between individual treatment start date and the first of 2 consecutive hemoglobin measurements at least 1.0 g/dL above baseline or 2 consecutive hemoglobin measurements at least 11.0 g/dL. Note: Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment.

Time frame:
Week 0 to Week 26
Reported as:
Median · Days
Time to Hemoglobin Response
DaysStandard of CarePROCRIT (Epoetin Alfa)
Time to Hemoglobin Response114 (43 to NA)41 (29 to 43)
Statistical analysis
  • Standard of Care vs PROCRIT (Epoetin Alfa) · Log Rank · p = <0.0001 (A priori threshold for statistical significance p=0.05)

Adverse events

Collected over 26 weeks or early withdraw. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care—14/39 (35.9%)34/39 (87.2%)
PROCRIT (Epoetin Alfa)—39/118 (33.1%)99/118 (83.9%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventStandard of CarePROCRIT (Epoetin Alfa)
Acute Myocardial InfarctionCardiac disorders3/391/118
Renal FailureRenal and urinary disorders3/390/118
Cardiac Failure CongestiveCardiac disorders2/394/118
UrosepsisInfections and infestations2/390/118
PneumoniaInfections and infestations1/395/118
Renal Failure AcuteRenal and urinary disorders0/395/118
Urinary Tract InfectionInfections and infestations0/394/118
BradycardiaCardiac disorders1/390/118
GastroenteritisInfections and infestations1/391/118
OesteomyelitisInfections and infestations1/390/118
Most frequent other events
Showing 10 of 42
Most frequent other events
EventStandard of CarePROCRIT (Epoetin Alfa)
Urinary Tract InfectionInfections and infestations9/3921/118
VomitingGastrointestinal disorders8/3922/118
Skin LacerationInjury, poisoning and procedural complications6/3924/118
Upper Respiratory Tract InfectionInfections and infestations2/3920/118
DiarrhoeaGastrointestinal disorders6/3919/118
ContusionInjury, poisoning and procedural complications6/3917/118
Oedema PeripheralGeneral disorders5/3913/118
HyperkalaemiaMetabolism and nutrition disorders5/392/118
ConstipationGastrointestinal disorders4/396/118
ExcoriationInjury, poisoning and procedural complications4/398/118

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Standard of CarePROCRIT (Epoetin Alfa)Total
<=18 years000
Between 18 and 65 years246
>=65 years37114151
Age Continuous
Age Continuous(Years)Standard of CarePROCRIT (Epoetin Alfa)Total
Mean84.4 ± 10.984.1 ± 9.284.1 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Standard of CarePROCRIT (Epoetin Alfa)Total
Female3390123
Male62834
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2006
First posted
Jun 20, 2006
Start
Jul 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
May 13, 2013
Last update
May 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00337935
Collaborators
Ortho Biotech Clinical Affairs, L.L.C.
Responsible party
Sponsor
First posted
Jun 20, 2006
Start date
Jul 2006
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
May 13, 2013
Last update
May 13, 2013

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion